Is Pfizer Stock Still a Buy After an Unexpected Setback?

Its long-term growth plan just hit a small bump in the road.With Pfizer (PFE 0.42%) stock badly underperforming the market over the past three years, falling by 32% while the market rose by close to the same amount, the last thing shareholders want to hear is news of another setback. Alas, the latest stumble was a somewhat unexpected one, and now the company will probably not realize revenue from one of its programs.But is the stock still worth buying in hopes of a recovery over the long term? To answer tha ...